Villani 1992.

Methods	RCT Open‐label Loss to follow‐up reported: yes
Participants	Symptomatic recent‐onset AF lasting > 1 hour, being at least the second episode. n = 76 Men: 49% Age (mean): 65 (range 37–85) years Structural heart disease: 86%. LAD: 38 mm. LVEF: NS
Interventions	Amiodarone 200 mg/day vs disopyramide 500 mg/day Method of AF cardioversion: pharmacological 74%, electrical 26% Warfarin discretionary
Outcomes	At 14 months: Mortality Adverse effects AF recurrence Symptomatic recurrence
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Reported that participants were randomised, but method employed not described.
Allocation concealment (selection bias)	Unclear risk	Method of concealment not described.
Blinding (performance bias and detection bias) All outcomes	High risk	Open‐label study.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Withdrawals and reasons for withdrawals well described. No participants lost to follow‐up.
Selective reporting (reporting bias)	Low risk	All prespecified outcomes of interest and all expected outcomes adequately reported.
Other bias	Low risk	No other bias apparent.